Navigation Links
Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting

FORT WORTH, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE: VRX), today announced six data presentations on Acanya Gel at the 67th Annual Meeting of the American Academy of Dermatology (AAD), taking place March 6 - 10, 2009, at the Moscone Center, San Francisco. The presentations demonstrate the efficacy and safety of once daily Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) in treating patients with moderate to severe acne vulgaris.

"Data to be presented at AAD will confirm the superior efficacy of Acanya Gel over active ingredients and vehicle for both inflammatory and non-inflammatory acne lesions, while showing favorable safety and tolerability in patients with moderate to severe acne vulgaris," said Steve Clark, president of Coria Laboratories. "Other highlights include a presentation on how Acanya Gel was developed to enhance the bioavailability of benzoyl peroxide while minimizing the risk of skin irritation, a discussion on Acanya Gel's role in effective management of adolescent acne, and a session on the importance of Patient Reported Outcomes in the treatment of acne vulgaris."

Following are details for each poster presentation. (All times are Pacific Standard Time. All presentations are located in Moscone Center North, Hall E)

Friday, March 6, 2009, 11:20 a.m.

Abstract #717

Poster Discussion: Can delivery be enhanced and skin irritation minimized using a lower concentration of benzoyl peroxide in a fixed combination product?

Presenter: Jim Del Rosso, D.O., Las Vegas Skin & Cancer Clinic, Las Vegas, Nevada

Friday, March 6, 2009, 11:30 a.m.

Abstract #718

Poster Discussion: Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne

Presenter: Michael Gold, M.D., Tennessee Clinical Research Center, Nashville, Tennessee

Friday, March 6, 2009, 12:30 p.m.

Abstract #724

Poster Discussion: Patient reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2,813 subjects

Presenter: Jonathan Weiss, M.D., Gwinnett Clinical Research Center, Snellville, Georgia

Friday, March 6, 2009, 2:50 p.m.

Abstract #738

Poster Discussion: Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne

Presenter: Diane Thiboutot, M.D., Department of Dermatology, the Pennsylvania State University College of Medicine, Hershey, Pennsylvania

Friday, March 6, 2009, 3:00 p.m.

Abstract #739

Poster Discussion: Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once-daily treatment of moderate to severe acne

Presenter: Diane Thiboutot, M.D., Department of Dermatology, the Pennsylvania State University College of Medicine, Hershey

Friday, March 6, 2009, 3:10 p.m.

Abstract #740

Poster Discussion: Managing moderate to severe acne in adolescents: Benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1,755 subjects

Presenter: Lawrence Eichenfield, M.D., Department of Dermatology, University of California, San Diego School of Medicine, San Diego, California

About Acanya Gel

Acanya Gel is the only FDA-approved fixed combination antibiotic and benzoyl peroxide (BPO) medication for once-daily treatment of both non-inflammatory and inflammatory lesions of acne. Formulated in an aqueous-based, alcohol-free gel, Acanya Gel was optimized to provide enhanced bioavailability of BPO, creating an effective and well tolerated product. In pivotal Phase III clinical trials, Acanya Gel showed superior efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent tolerability and very high patient satisfaction scores.

Acanya Gel was developed by Arcutis Pharmaceuticals, now a part of Coria Laboratories, a division of Valeant Pharmaceuticals International. Acanya Gel is protected by two U.S. Patents and has pending patent applications. More information about Acanya Gel can be obtained at

Indication and Important Safety Information for Acanya Gel

Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. In controlled clinical trials, the following application-site adverse reactions occurred in less than 0.2% of patients treated with Acanya Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and application-site irritation (0.1%). Patients are advised to avoid applying in mouth, eyes, or nose or on lips, and to minimize sun exposure following the application of Acanya Gel.

About Coria Laboratories

Coria Laboratories is the dermatology division of Valeant Pharmaceuticals International. With its acquisition of Coria Laboratories Ltd. in October 2008, Valeant has created a fully integrated portfolio of specialty pharmaceutical products focused on medical dermatology. Coria Laboratories combines a commercial organization with management expertise, a proven sales force and a goal of developing and marketing innovative products, positioning Coria Laboratories for dermatology industry leadership going forward. Coria Laboratories is committed to establishing a tradition of unparalleled service to the dermatology community, with the critical goal of supporting dermatologists and their practices through greater patient satisfaction with therapy. For more information, please visit

About Valeant Pharmaceuticals:

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at


This press release contains forward-looking statements, including, but not limited to, statements regarding the efficacy of Acanya and favorable safety profile. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the data to be presented at AAD that will confirm the superior efficacy of Acanya Gel and other risks and uncertainties discussed in the company's annual report or Form 10-K for the years ended December 31, 2007 and other filings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.


     Investors:                         Media:
     Laurie W. Little                   Carole Melis
     949-461-6002                       650-342-5686

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
(Date:10/9/2015)... Beach, CA (PRWEB) , ... October 09, 2015 ... ... is now offering a special promotion on Invisalign, the orthodontic system that uses ... reasons. The aligners are almost invisible against the teeth, which allow patients to ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... has announced the final product specifications for TRACTUS, the world’s first sterile field ... the United States in response to the FDA’s recent Unique Device Identifier (UDI) ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the ... walks of life to save money on the high cost of their prescription ... per medication, individuals and families can receive their medications delivered direct from over ...
Breaking Medicine News(10 mins):
... Medicine, Radiation Therapy after Lumpectomy// and five years of treatment ... both cancer recurrence and new tumors in older women with ... standard care for younger patients, it is has been shown ... lead author Ann M. Geiger, M.P.H., Ph.D., an associate professor ...
... found that endurance athletes with ventricular arrhythmias also possess ... in endurance sports come up with a relatively rare ... arrhythmia, the heart beats at an abnormal rate and ... majority of athletes with VA also have worthless right ...
... beneficial traits shape up in natural populations,// but one is ... traits. Two theories have tried to address this challenge – ... ,The theory of hitchhiking has indicated that ... frequent in natural populations when they "hitch a ride" with ...
... right kind of diet is said to have a beneficial effect ... promote good health in men are the following // ,Vegetables ... health boosters while the non-vegetarian food like oysters, shrimps and deep ... aid in the digestion of proteins and nutrients and also help ...
... twenties group who take the preventive test for cervical cancer viz. ... in 2005-06 from 80% in 1995. A parallel trend was observed ... said to avoid this test due to the painful and invasive ... the young women population who are avoiding this test are the ...
... states that fat men are able to handle heart attacks ... team of researchers from University of California. ... heart attacks, they were able to recuperate better than thin ... of fat reserves in their body which is helping them ...
Cached Medicine News:
(Date:10/9/2015)... -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today announced ... Society of Emergency Medicine (EuSEM) meeting to be held October ... the Lingotto Congress Centre in Turin, Italy ... medicine practitioners in the world with over 2000 delegates in ... previously announced phase 2 bunionectomy trial will also be included.  ...
(Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. ... focused on gastrointestinal and cardio-renal diseases, today announced ... candidate, tenapanor, will be presented at the 2015 ... findings will include measures of sustained response in ... blind, placebo-controlled, randomized Phase 2 trial. The meeting ...
Breaking Medicine Technology:
... ,, NEW YORK , Aug. 3 ITelagen, a ... it was selected by Manhattan ,s Physician Group (MPG) to host, ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... for staff members. , , ...
... PHILADELPHIA , Aug. 3 ... a safe, isotope-free alternative to traditional radiation therapy ... focus of 14 clinical research studies presented at ... Meeting.  According to Xoft, Inc., the clinical benefits ...
Cached Medicine Technology:
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
... RNA, Or Fluorescent Tags. Accurate quantitation of minute ... life science research. The RF-Mini 150 Fluorometer offers ... small as 1ng/ml of DNA specific Hoechst Dye. ... emission filters, the RF-Mini 150 can measure RNA ...
Medicine Products: